Name: National EBS Association (NEBSA) 2014 Annual Meeting
Start: 2014-02-17T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

Standard Essential Patents

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Hosts

Name

Ed Lavergne

Person title

Senior Principal

Principal Edwin Lavergne (DC) will present at the NEBSA 2014 Annual Meeting.

National EBS Association (NEBSA) 2014 Annual Meeting

Hosts

Association of Corporate Patent Counsel Summer Meeting 2025

Federal Circuit Reverses Injunction That Barred Clinical Trials in Jazz v. Avadel

HHS Sets Most-Favored-Nation Price Targets for Pharmaceuticals

How Trump’s Latest Drug Price EO Could Impact Pharma

Can Clinical Trials Negate Patentability for Pharma Inventions?

Trump’s Drug Price Executive Order: What Drugmakers Should Know

Federal Circuit: PTE for Reissue Patents Should Be Calculated From Original Patent’s Issue Date

Recent Decisions and FTC Challenges Dictate Caution When Listing Patents in the Orange Book

Biologics and Biosimilars Landscape 2024: IP, Policy, and Market Developments

Hatch-Waxman 201

How a Second Trump Presidency Could Shape IP